# BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 Revenue by Business Segment by Product and Service

- Company: BridgeBio Pharma, Inc. (BBIO)
- Statement: BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/bbio/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-q3-income-statement/revenue-by-business-segment-by-product-and-service
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-revenue-by-business-segment-by-product-and-service-sankey.png

## Chart details: Revenue by Business Segment by Product and Service

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 353,171,000 US dollars
- **Total cost of revenues**: 20,450,000 US dollars
- **Gross profit (calculated)**: 332,721,000 US dollars
- **Operating expenses (calculated)**: 344,360,000 US dollars
- **Loss from operations**: negative 11,639,000 US dollars
- **Total other expense, net**: negative 47,628,000 US dollars
- **Loss before income taxes**: negative 59,267,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 60,496,000 US dollars
- **Reportable Segment - License and services revenue**: 79,314,000 US dollars
- **Reportable Segment - Net product revenue**: 253,346,000 US dollars
- **Reportable Segment - Royalty revenue**: 20,511,000 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 143,506,000 US dollars
- **Selling, general and administrative**: 200,854,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.

## Key Takeaways

- The single reportable segment accounts for 100% of the $353.17 M of revenue.
- Net product revenue was $253.35 M, 72% of the total, with license at $79.31 M.
- License and services revenue rose 9.5 times in a year, from $8.31 M to $79.31 M.
- Royalty revenue rose from $4.28 M to $20.51 M on Beyonttra sales in the EU and Japan.

## The Unvarnished Truth

### One segment, three revenue lines, and product sales carry 72%

The business view is one segment: the Reportable Segment accounts for 100% of the $353.17 M of revenue. Inside it, net product revenue is $253.35 M, license and services revenue $79.31 M, and royalty revenue $20.51 M. Product sales carry 72% of the total, and the rest is a mix of milestones and royalties from partners. The company says it runs one business, so this view splits one business into three lines, not three businesses. That is the filing's own framing, not ours.

The quarter's growth came from the smaller lines. License and services revenue rose from $8.31 M to $79.31 M, or 9.5 times its level a year earlier, while net product revenue grew 134%. The filing ties that license jump to the $75.0 M milestone, so product sales are the steady part and license revenue is the lumpy part. Nine months tell the same story, with license revenue down 29% from a year earlier while product sales climbed.

What it means: one name, three businesses. Royalty revenue rose from $4.28 M to $20.51 M on Beyonttra sales in the EU and Japan, and the filing expects more from partners such as Bayer and Alexion. Products that sell, licenses that pay out once, and royalties that depend on partners' sales do not behave alike. Mixing them into one segment hides which line is carrying the company. Will royalty revenue keep rising as partners sell more, or will milestones keep the top line lumpy?

## Intelligent Insights for Investors

### What is inside the biggest piece of BridgeBio's sales?

The reportable segment is the whole picture: its listed products brought in 100% of sales this quarter, and product revenue made up 72% of them.

### Which parts of BridgeBio's sales by business drove the change over the past year?

Net product revenue did most of the work: it grew 134% this quarter and accounted for 62% of the increase in revenue.

## Intelligent Insights for Suppliers

### How much does BridgeBio depend on the biggest piece of its sales by business?

Heavily: product revenue brought in 72% of these sales this quarter, against 22% for license and services revenue, the next largest.
